Logo

Novation Inks Supply Deal for Bayer Molecular Diagnostics Products

Jul 15, 2004

NEW YORK, July 15 (GenomeWeb News) - Novation, the supply company for VHA and University HealthSystem Consortium, has signed a three-year agreement to make Bayer Diagnostics' molecular diagnostics products available to the 2,300 hospitals served by the two healthcare alliances.

 

The pact covers Bayer's Versant bDNA assays for hepatitis C and HIV, Trugene HIV-1 genotyping kits and OpenGene DNA sequencing system. Financial terms of the agreement were not disclosed.

 

According to a statement released today by Irving, Texas-based Novation, the agreement extends to healthcare organizations that purchase supplies through HealthCare Purchasing Partners International, which markets Novation purchasing pacts to non-members of VHA and UHC.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.